Dan Theodorescu, MD, PhD Director, Arizona Cancer Center Professor, Urology Professor, Cellular and Molecular Medicine Chair, UACC (520) 626-2548 theodorescu@arizona.edu TEST EDIT Affiliated Faculty Molecular Medicine Grad Program
Subramaniyan, Boopathi, et al. “Loss of the Y Chromosome Drives Cancer Metabolic Reprogramming.”. BioRxiv, Aug. 2025, https://doi.org/10.1101/2025.08.26.672471.
Chen, Xingyu, et al. “Concurrent Loss of the Y Chromosome in Cancer and T Cells Impacts Outcome.”. Nature, vol. 642, no. 8069, June 2025, pp. 1041-50, https://doi.org/10.1038/s41586-025-09071-2.
Chaudhary, Prakash, et al. “Sex Differences in Bladder Cancer: Understanding Biological and Clinical Implications.”. Biol Sex Differ, vol. 16, no. 1, May 2025, p. 31, https://doi.org/10.1186/s13293-025-00715-6.
Abdel-Hafiz, Hany A, et al. “Single-Cell Profiling of Murine Bladder Cancer Identifies Sex-Specific Transcriptional Signatures With Prognostic Relevance.”. IScience, vol. 26, no. 9, Sept. 2023, p. 107703, https://doi.org/10.1016/j.isci.2023.107703.
Abdel-Hafiz, Hany A, et al. “Y Chromosome Loss in Cancer Drives Growth by Evasion of Adaptive Immunity.”. Nature, vol. 619, no. 7970, July 2023, pp. 624-31, https://doi.org/10.1038/s41586-023-06234-x.
Schafer, Johanna M, et al. “Sex-Biased Adaptive Immune Regulation in Cancer Development and Therapy.”. IScience, vol. 25, no. 8, Aug. 2022, p. 104717, https://doi.org/10.1016/j.isci.2022.104717.
Tu, Megan M, et al. “Inhibition of the CCL2 Receptor, CCR2, Enhances Tumor Response to Immune Checkpoint Therapy.”. Commun Biol, vol. 3, no. 1, Nov. 2020, p. 720, https://doi.org/10.1038/s42003-020-01441-y.
Tu, Megan M, et al. “Targeting DDR2 Enhances Tumor Response to Anti-PD-1 Immunotherapy.”. Sci Adv, vol. 5, no. 2, Feb. 2019, p. eaav2437, https://doi.org/10.1126/sciadv.aav2437.
